Monopar Therapeutics announced Phase 2 trial results for ALXN1840 (tiomolibdate choline) in treatment-experienced Wilson disease patients. The study demonstrated stabilization or improvement in liver pathology across multiple histologic measures, significant neurologic improvements in UWDRS scores, and improved quality of life. The drug was generally well tolerated with mostly Grade 1-2 adverse events.

Monopar Therapeutics announced Q1 2026 financial results with cash reserves of $137.5 million and a net loss of $3.9 million. The company presented Phase 3 FoCus trial data showing ALXN1840 (tiomolibdate choline) demonstrated greater neurologic benefit versus standard-of-care in Wilson disease patients. The NDA submission to the FDA remains on track for mid-2026, with new Chief Commercial and Strategy Officer Susan Rodriguez leading commercial readiness activities.

Monopar Therapeutics announced 2025 financial results with a net loss of $13.7 million and cash reserves of $140.4 million expected to support operations through at least December 2027. The company plans to submit a New Drug Application for ALXN1840 in mid-2026 for Wilson disease treatment, supported by positive clinical data presentations and FDA interactions. The company also strengthened its leadership team and balance sheet through a $91.9 million public offering.

Monopar Therapeutics presented new data at AASLD showing that ALXN1840 (tiomolybdate choline) rapidly improved copper balance in Wilson disease patients through increased fecal copper excretion.

Monopar Therapeutics is conducting a $135 million underwritten offering of common stock and pre-funded warrants, with plans to use proceeds for general corporate purposes and a stock repurchase from Tactic Pharma.

Monopar Therapeutics published a Letter to the Editor in the Journal of Hepatology, reanalyzing their Phase 2 ALXN1840-WD-204 study for Wilson disease. The new analysis shows that ALXN1840 statistically significantly improved copper balance by accounting for additional routes of copper loss.

Monopar Therapeutics has in-licensed ALXN-1840, a late-stage drug candidate for Wilson disease, from Alexion, AstraZeneca Rare Disease. The company also has two novel radiopharma clinical trials active and enrolling patients with advanced solid cancers.

Monopar Therapeutics, a clinical-stage biotechnology company, announced the pricing of a $19.2 million public offering of its common stock at $16.25 per share. The proceeds will be used for general corporate purposes, including research and development, clinical trials, and working capital.

WILMETTE, Ill., June 25, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced that its abstract titled “Evaluation of Anti-uPAR Antibody as a Radiopharmaceutical for Imaging and Treatment of Solid Tumors” has been accepted as a “Top-Rated Oral Presentation” within the Scientific Program of the European Association of Nuclear Medicine (EANM) 2024 Annual Congress to be held on October 19-23, 2024 in Hamburg, Germany.

Highlights:

WILMETTE, Ill., May 24, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that after a career spanning more than 35 years, Monopar’s Chief Financial Officer, Kim R. Tsuchimoto, will be retiring.

After losing some value lately, a hammer chart pattern has been formed for Monopar Therapeutics (MNPR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.